Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

NEUROFYSIOTERAPIEN ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   10.0% 10.8% 8.9% 9.3% 11.1% 9.2% 19.6% 19.6%   Credit score (0-100)   26 22 26 26 21 27 6 6   Credit rating   BB BB BB BB BB BB B B   Credit limit (kDKK)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   613 581 542 485 579 730 0.0 0.0   EBITDA   28.0 11.7 24.8 -35.5 17.6 16.9 0.0 0.0   EBIT   28.0 11.7 24.8 -35.5 17.6 16.9 0.0 0.0   Pre-tax profit (PTP)   27.2 8.7 20.4 -38.4 18.2 18.1 0.0 0.0   Net earnings   20.3 6.5 14.9 -30.4 13.8 12.9 0.0 0.0   Pre-tax profit without non-rec. items   27.2 8.7 20.4 -38.4 18.2 18.1 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 62.7 0.0 0.0   Shareholders equity total   239 246 261 230 244 257 194 194   Interest-bearing liabilities   0.9 0.9 0.9 0.9 0.9 1.2 0.0 0.0   Balance sheet total (assets)   551 618 599 398 397 406 194 194   Net Debt   -388 -467 -484 -262 -310 -242 -194 -194     See the entire balance sheet 1000.0 Volume  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   613 581 542 485 579 730 0.0 0.0   Gross profit growth   83.9% -5.2% -6.8% -10.6% 19.4% 26.2% -100.0% 0.0%   Employees   1 1 1 1 1 1 0 0   Employee growth %   -50.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   551 618 599 398 397 406 194 194   Balance sheet change%   79.2% 12.3% -3.2% -33.5% -0.4% 2.4% -52.1% 0.0%   Added value   28.0 11.7 24.8 -35.5 17.6 16.9 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 63 -63 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   1.0 2.0 3.0 -1.0 1.0 2.0 0.0 0.0   1000.0 Profitability  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   4.6% 2.0% 4.6% -7.3% 3.0% 2.3% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   6.5% 2.0% 4.1% -7.1% 4.6% 4.5% 0.0% 0.0%   ROI %   12.2% 4.8% 9.7% -14.4% 7.7% 7.2% 0.0% 0.0%   ROE %   8.9% 2.7% 5.9% -12.4% 5.8% 5.1% 0.0% 0.0%   1000.0 Solidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Equity ratio %   43.5% 39.7% 43.5% 57.8% 61.5% 63.2% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -1,386.2% -3,975.7% -1,956.0% 738.6% -1,767.7% -1,427.7% 0.0% 0.0%   Gearing %   0.4% 0.4% 0.3% 0.4% 0.4% 0.5% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   165.7% 355.4% 506.9% 327.2% 1.0% 0.0% 0.0% 0.0%   1000.0 Liquidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Quick Ratio   1.6 1.6 1.7 2.1 2.3 2.1 0.0 0.0   Current Ratio   1.6 1.6 1.7 2.1 2.3 2.1 0.0 0.0   Cash and cash equivalent   388.5 467.8 485.1 263.2 311.3 242.9 0.0 0.0   1000.0 Capital use efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   200.6 207.1 222.0 191.6 205.4 157.3 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   28 12 25 -36 18 17 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   28 12 25 -36 18 17 0 0   EBIT / employee   28 12 25 -36 18 17 0 0   Net earnings / employee   20 7 15 -30 14 13 0 0